Fairvalue-Calculator Fairvalue-Calculator
EN DE

Meta Biomed Co (059210) Fair Value & Analysis

Healthcare · KR · Market cap 105B KRW

Price3,575 KRW
Fair Value9,875 KRW
Upside+176.2%
Quality95/100
Evidence: Medium Range 5,762 KRW – 11,021 KRW

Fair value as of: Jun 25, 2026

Analysis

Meta Biomed Co (059210) currently trades at 3,575 KRW, while our model-based Fair Value estimate is 9,875 KRW — implying the stock looks roughly 176.2% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Meta Biomed Co., Ltd. engages in the research and development, production, and marketing of dental and surgical materials in South Korea and internationally. The company's dental products include endodontics, endodontic materials, restorative materials, and bone graft materials. It also offers suture products comprising multifilament and monofilament products, as well as orthopedics; bone products consisting of bone graft substitutes and cement; and cosmetic medical products, as well as ultrasonic imaging diagnosis devices. The company was formerly known as Metadental Co., Ltd. and changed its name to Meta Biomed Co., Ltd. in 2001. Meta Biomed Co., Ltd. was founded in 1990 and is headquartered in Cheongju, South Korea.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Meta Biomed Co (059210) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 9,875 KRW versus a price of 3,575 KRW — about +176% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 059210?
Our 21-model fair value for Meta Biomed Co is 9,875 KRW (as of Jun 25, 2026), built from audited fundamentals. The current price is 3,575 KRW.
What is the quality score of 059210?
Meta Biomed Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.